We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.60 | -1.78% | 33.10 | 32.95 | 33.85 | 33.95 | 32.95 | 33.95 | 1,864,058 | 16:35:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 195.88 | 179.87M |
income for the period - - - - (453) 8,384 7,931 -------------------------- --------- --------- --------- ---------- --------- ---------- -------- Balance 31 December 2014 2,641 29,388 1,995 (329) (103) 37,188 70,780 -------------------------- --------- --------- --------- ---------- --------- ---------- --------
Consolidated Cash Flow Statements
Year ended Year ended 31 December 31 December 2013 2014 Restated* Note GBP 000s GBP 000s Cash flows from operating activities Cash generated from operations 9 13,451 11,897 Tax paid (2,028) (2,516) Cash flows from operating activities 11,423 9,381 ---------------------------------------------- ------------ ------------ Investing activities Interest received 48 50 Dividend received 72 420 Payment of deferred consideration - (20) Development costs capitalised (58) (63) Purchase of property, plant and equipment (111) (298) Purchase of other intangible assets (2,817) (9,534) Investment in joint venture (499) - ---------------------------------------------- ------------ ------------ Net cash used in investing activities (3,365) (9,445) ---------------------------------------------- ------------ ------------ Financing activities Interest paid and similar charges (986) (1,232) Loan issue costs - (500) Loan to joint venture (503) - Proceeds from exercise of share options 8 82 Dividend paid (2,398) (2,040) Receipt from borrowings 2,750 28,500 Repayment of borrowings (4,500) (30,725) Net cash used in financing activities (5,629) (5,915) ---------------------------------------------- ------------ ------------ Net movement in cash and cash equivalents 2,429 (5,979) Cash and cash equivalents at the beginning of the period (1,438) 4,613 Exchange gains / (losses)on cash and cash equivalents 29 (72) ---------------------------------------------- ------------ ------------ Cash and cash equivalents at the end of the period 10 (1,020) (1,438) ------------------------------------------ ------ ------------ ------------
*Restated due to the adoption of IFRS 11, please see note 11
1. Basis of preparation
The financial information set out in the announcement does not constitute the Group's statutory accounts for the year ended 31 December 2014 or 31 December 2013. The auditors reported on those accounts; their report was (i) unqualified, (ii) did not include references to any matters to which the auditors drew attention by way of emphasis without qualifying their report and (iii) did not contain statements under section 498 (2) or (3) of the Companies Act 2006. The statutory accounts for the year ended 31 December 2014 have not yet been delivered to the Registrar of Companies. The statutory accounts for the year ended 31 December 2013 were delivered to the Registrar of Companies as published on the Group's website on 10 April 2014.
2. Finance costs
Year ended Year ended 31 December 31 December 2013 2014 Restated GBP 000s GBP 000s ----------------------------------------------------- ------------ ------------ Interest payable and similar charges On loans and overdrafts (968) (1,222) Amortised finance issue costs (104) (22) Notional interest (18) (37) ----------------------------------------------------- ------------ ------------ (1,090) (1,281) Interest income 48 50 Other finance income / (charges) Foreign exchange movement on euro denominated debt 28 (72) 28 (72) Finance costs - net (1,014) (1,303) ----------------------------------------------------- ------------ ------------
Notional interest relates to the unwinding of the discount applied to provisions.
3. Taxation
Analysis of charge in period.
Year ended Year ended 31 December 31 December 2014 2013 GBP 000s GBP 000s ---------------------------------------- ------------ ------------ United Kingdom corporation tax at 21.5% (2013: 23.25%) In respect of current period 1,870 2,242 Adjustment in respect of prior periods (38) 106 1,832 2,348 Deferred tax Origination and reversal of temporary differences (60) 77 Taxation 1,772 2,425 ---------------------------------------- ------------ ------------
4. Dividends
Year ended Year ended 31 December 31 December 2014 2013 GBP Pence/share 000s Pence/share GBP 000s Amounts recognised as distributions to owners in the year Interim dividend for the prior financial year 0.303 800 0.275 666 Final dividend for the prior financial year 0.605 1,598 0.550 1,374 ----------------------------------------- ----------- ----- ----------- ------------ 2,398 2,040 Interim dividend for the current financial year 0.333 880 0.303 800 ----------------------------------------- ----------- ----- ----------- ------------
The proposed final dividend of 0.667 pence per share for the current financial year was approved by the Board of Directors on 24 March 2015 and is subject to the approval of shareholders at the Annual General Meeting. The proposed dividend has not been included as a liability as at 31 December 2014 in accordance with IAS 10 Events After the Balance Sheet Date. The interim dividend for the current financial year was paid on 15 January 2015. Subject to shareholder approval, the final dividend will be paid on 15 July 2015 to shareholders who are on the register of members on 19 June 2015.
5. Earnings per share (EPS)
Basic EPS is calculated by dividing the earnings attributable to ordinary shareholders by the weighted average number of ordinary shares in issue during the year. For diluted EPS, the weighted average number of ordinary shares in issue is adjusted to assume conversion of all dilutive potential ordinary shares.
A reconciliation of the weighted average number of ordinary shares used in the measures is given below:
Year ended Year ended 31 December 31 December 2014 2013 For basic EPS calculation 264,148,367 250,836,337 Employee share options 1,454,986 2,020,036 Conversion of Convertible Unsecured Loan Stock (CULS) - 12,154,481 -------------------------------------- ------------ ------------ For diluted EPS calculation 265,603,353 265,010,854 -------------------------------------- ------------ ------------
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions